HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A  by Bolduan, Sebastian et al.
Virology 440 (2013) 190–203Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
E-mjournal homepage: www.elsevier.com/locate/yviroHIV-1 Vpu affects the anterograde transport and the glycosylation pattern
of NTB-ASebastian Bolduan a, Philipp Hubel a, Tatjana Reif a, Veronika Lodermeyer a, Kristin Ho¨hne d,
Joe¨lle V. Fritz c, Daniel Sauter b, Frank Kirchhoff b, Oliver T. Fackler c,
Michael Schindler d, Ulrich Schubert a,n
a Institute of Virology, University of Erlangen-Nuremberg, Germany
b Institute of Molecular Virology, Ulm University Medical Center, Germany
c Department of Infectious Diseases, Virology, University Hospital Heidelberg, Germany
d Institute of Virology, Helmholtz Zentrum Munich, Germanya r t i c l e i n f o
Article history:
Received 3 December 2012
Returned to author for revisions
22 February 2013
Accepted 25 February 2013
Available online 22 March 2013
Keywords:
Vpu
NTB-A
SLAMF6
HIV-1
SIV
Pulse-chase
N-linked glycosylation
Tetherin22/$ - see front matter & 2013 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2013.02.021
esponding author. Fax: þ49 9131 8526 182.
ail address: Ulrich.Schubert@viro.med.uni-erla b s t r a c t
HIV-1 Vpu induces downregulation of cell surface NTB-A to evade lysis of HIV-1 infected cells by NK
cells. Here we show that Vpu affects the anterograde transport and the glycosylation pattern of NTB-A
by a mechanism that is distinct from the Vpu induced downregulation of CD4 and tetherin. In the
presence of Vpu, only the high mannose form of NTB-A was detectable, suggesting that Vpu prevented
the formation of the mature form of NTB-A. This phenomenon is associated with the ability of Vpu to
downregulate cell surface NTB-A by retention of NTB-A within the Golgi-compartment. Furthermore,
the Vpu-mediated effect on NTB-A glycosylation is highly conserved among Vpu proteins derived from
HIV-1 and SIV and corresponds to the level of downregulation of NTB-A. Together, these results suggest
that the reduction of NTB-A from the cell surface is associated with the Vpu-mediated effect on the
glycosylation pattern of newly synthesized NTB-A molecules.
& 2013 Elsevier Inc. All rights reserved.Introduction
The human immunodeﬁciency virus type 1 (HIV-1) accessory
protein Vpu is a 15–20 kDa oligomeric type 1 integral membrane
phosphoprotein (Cohen et al., 1988; Maldarelli et al., 1993;
Strebel et al., 1988), which is encoded exclusively by HIV-1 and
related simian immunodeﬁciency viruses (SIVs), but not by the
majority of SIVs and HIV-2. Vpu induces the degradation of newly
synthesized CD4, by retaining it in the endoplasmic reticulum
(ER) (Magadan et al., 2010) and thereby targeting CD4 to the ER-
associated protein degradation (ERAD)-pathway (Binette et al.,
2007; Magadan et al., 2010; Schubert et al., 1998; Willey et al.,
1992). The cytoplasmic domain of Vpu contains a pair of highly
conserved serine residues, which are constitutively phosphory-
lated by the casein kinase 2 (CK-2) (Schubert et al., 1994).
This phosphorylation allows binding of the ß-transducin repeat
containing protein (ß-TrCP), a component of the Skp1-Cullin-
F-box (SCF) E3 ubiquitin ligase complex (Butticaz et al., 2007;ll rights reserved.
angen.de (U. Schubert).Margottin et al., 1998), which induces polyubiquitination of the
cytoplasmic domain of CD4 (Magadan et al., 2010). Consequently,
CD4 is retranslocated into the cytosol and degraded by the 26S
proteasome (Binette et al., 2007; Magadan et al., 2010; Schubert
et al., 1998). Furthermore, it was shown that Vpu supports HIV-1
virion release by counteracting the cellular restriction factor
tetherin (also known as CD317, BST-2 or HM1.24) (Neil et al.,
2008; Van Damme et al., 2008). The ability of Vpu to enhance
virion release directly correlates with its ability to downregulate
cell surface tetherin. The transmembrane (TM) domain of Vpu is
essential for interaction with tetherin and consequently for the
downregulation of tetherin from the cell surface (Banning et al.,
2010; Bolduan et al., 2011; Dube et al., 2010; Iwabu et al., 2009;
Rong et al., 2009). This physical interaction likely enables Vpu to
trap newly synthesized and recycling tetherin molecules at the
level of the trans-Golgi network (TGN) in order to reduce cell
surface exposure of the restriction factor (Dube et al., 2010;
Schmidt et al., 2011).
In addition to its role in tetherin antagonism and CD4 degra-
dation, the TM domain of Vpu was found to form a non-selective,
voltage gated ion channel in planar lipid bilayers (Ewart et al.,
1996; Schubert et al., 1996b), which was later continued for the
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TM domain prevents Vpu’s ion channel formation and impairs its
ability to regulate virion release (Schubert et al., 1996a), indicat-
ing a correlation between the ion channel activity of Vpu and
its augmentation of virus release. However, it was shown that
ion channel activity of Vpu is dispensable for counteraction
of tetherin (Bolduan et al., 2011; Kuhl et al., 2011; Skasko
et al., 2011).
Recently, it has been described that Vpu induces downregula-
tion of the coactivating NK cell receptor NK, T-cell, B-cell antigen
(NTB-A) (also termed CD352 or SLAMF6), as well as the activating
NK cell receptor PVR/CD155, from the cell surface to evade lysis of
HIV-1 infected cells by NK cells (Matusali et al., 2012; Shah et al.,
2010). However, the molecular mechanism of these Vpu induced
downregulations, particularly of NTB-A, has not been elucidated
so far.
NK cell-mediated degranulation requires two signals from acti-
vating and coactivating receptors (Sowrirajan and Barker, 2011).Fig. 1. The effect of wt Vpu on the glycosylation pattern of NTB-A and tetherin an
cotransfected with pNTB-A-2 and either AU1-tagged wt Vpu or an empty vector control.
and were then pulse labeled for 7 min with [35S]-methionine. Cells were chased fo
immunoprecipitated with an anti-NTB-A antibody, analyzed by SDS-PAGE and autoradio
the right. (B) Parallel cultures of 293 T cells were cotransfected with NTB-A isoform 1 an
were incubated in methionine free medium for 30 min and were then pulse labeled for 7
indicated cells were collected. NTB-A was immunoprecipitated with an anti-NTB-A anti
NTB-A isoform 1 glycosylation is given on the right. (C) Parallel cultures of 293T cells w
empty vector control. 24 h post transfection cells were incubated in methionine free me
were chased for up to 2 h and at each time point indicated cells were collected. Flag-tag
by SDS-PAGE and autoradiography. Quantiﬁcation of the Vpu induced degradation of tThe coactivating NK cell receptor NTB-A, which facilitates NK
cell-mediated cytotoxicity (Bottino et al., 2001; Flaig, Stark, and
Watzl, 2004), is a type I transmembrane glycoprotein and a
member of the signaling lymphocytic activation molecule (SLAM)
receptor family (Bottino et al., 2001). It has been suggested that
the Vpu induced downregulation of cell surface NTB-A is mechan-
istically distinct from the downmodulation of CD4 and tetherin
(Shah et al., 2010). Furthermore, Vpu does neither increase
internalization rates nor alters the steady state protein level of
NTB-A (Shah et al., 2010).
Here we demonstrate that in the presence of Vpu only the high
mannose form of NTB-A is detectable, suggesting that Vpu
prevents the formation of complex/hybrid-type glycosylated
NTB-A. Furthermore, this phenomenon is associated with the
transport of NTB-A to the cell surface.
The second cytoplasmic alpha helix of Vpu and/or its localiza-
tion in the Golgi-compartment appears to be critical to prevent
the formation of the mature form of NTB-A. The importance ofalyzed via pulse-chase kinetic analysis. (A) Parallel cultures of 293T cells were
24 h post transfection cells were incubated in methionine free medium for 30 min
r up to 6 h and at each time point indicated cells were collected. NTB-A was
graphy. Quantiﬁcation of the kinetics of NTB-A isoform 2 glycosylation is given on
d either AU1-tagged wt Vpu or an empty vector control. 24 h post transfection cells
min with [35S]-methionine. Cells were chased for up to 2 h, and at each time point
body, analyzed by SDS-PAGE and autoradiography. Quantiﬁcation of the kinetics of
ere cotransfected with Flag-tagged tetherin and either AU1-tagged wt Vpu or an
dium for 30 min and were then pulse labeled for 7 min with [35S]-methionine. Cells
ged tetherin was immunoprecipitated with anti-Flag M2 afﬁnity matrix, analyzed
etherin is given on the right.
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observation that this function is conserved among diverse HIV-1
and SIV strains. The only notable exceptions are Vpu proteins
derived from HIV-1 group N, which fail to affect the glycosylation
pattern of NTB-A and do not induce downregulation of cell
surface NTB-A. Altogether, our data suggest that Vpu inﬂuences
the glycosylation pattern of NTB-A, which correlates with a
decreased localization of NTB-A at the cell surface.Fig. 2. NTB-A remains Endo H sensitive in the presence of wt Vpu. Parallel cultures
of 293T cells were cotransfected with either pNTB-A-2 alone (B) or together with
AU1-tagged wt Vpu (A). 24 h post transfection cells were pulse labeled with
[35S]methionine for 7 min and chased for up to 2 h. NTB-A molecules were
immunoprecipitated with an anti-NTB-A antibody. Bead-bound material was split
and either treated with Endo H or left untreated. Samples were analyzed by SDS-
PAGE and autoradiography. (C) Quantiﬁcation of the kinetics of NTB-A isoform
2 glycosylation (the ratio of 60 kDa/50 kDa NTB-A is given on the left and the
relative amount of 37 kDa NTB-A is given on the right).Results
HIV-1 Vpu modulates the glycosylation pattern of NTB-A, but not of
tetherin
Recently, it was shown that HIV-1 Vpu downregulates cell
surface NTB-A, thereby protecting HIV-1 infected cells from lysis
by NK cells (Shah et al., 2010). At ﬁrst, we evaluated a potential
effect of Vpu on the protein turnover of NTB-A by pulse-chase
experiments in 293T cells. In general, NTB-A is expressed in NK-,
B- and T cells, and is not present on the surface of 293T cells
(Valdez et al., 2004). 293T cells were cotransfected with an
expression plasmid that is under control of the CMV promoter
expressing NTB-A isoform 2 (pNTB-A-2) together with an expres-
sion plasmid for AU1-tagged wt Vpu (pCG-HIV-1 M NL4-3 wt
Vpu-AU1-IRES-GFP), or an empty vector control. 24 h post trans-
fection cells were pulse labeled with [35S]methionine and sub-
jected to a chase period for up to 6 h. Cell lysates were
immunoprecipitated with anti-NTB-A antibodies, separated by
SDS-PAGE and analyzed by autoradiography (Fig. 1A). The NTB-A
protein was initially synthesized as a single band with a mole-
cular weight of approximately 50 kDa, which most likely repre-
sents the high mannose version of NTB-A (Fig. 1A, upper left
panel). After approximately 15 min of chase, a higher molecular
version of NTB-A migrating at approximately 60 kDa starts to
emerge, which most likely represents the complex/hybrid-type
glycosylated form of NTB-A (Fig. 1A, lower left panel). In contrast,
the formation of the 60 kDa band of NTB-A was barely detectable
in the presence of Vpu (Fig. 1A upper left panel). The quantiﬁca-
tion of the relative amount of the 50 kDa and 60 kDa version of
NTB-A by phosphoimager analysis clearly demonstrates that Vpu
prevents the formation of the mature form of NTB-A during the
6 h chase period (Fig. 1A, right panel). Similar results were
obtained with NTB-A isoform 1 (pCG-NTB-A isoform 1)
that contains an alanine insertion at amino acid position 266
(Fig. 1B).
Due to this observation we investigate whether other cellular
targets of Vpu also share this phenomenon. Therefore, we ana-
lyzed whether Vpu affects the glycosylation pattern of tetherin.
Tetherin contains two N-linked glycosylation sites at amino acid
positions 65 and 92 (Kupzig et al., 2003) and was shown to
become intensively glycosylated (Perez-Caballero et al., 2009).
293T cells were cotransfected with expression plasmids for Flag-
tagged Tetherin (pCMV-Flag-Tetherin) and AU1-tagged wt Vpu or
an empty vector control. 24 h post transfection cells were pulse
labeled with [35S]methionine and subjected to a pulse-chase
protocol as conducted in Fig. 1A, B. In contrast to NTB-A, Vpu
had no effect on the glycosylation pattern of tetherin (Fig. 1C, left
side), while the stability of tetherin was slightly reduced in the
presence of Vpu, which is consistent with previous reports
(Douglas et al., 2009; Gofﬁnet et al., 2010; Mangeat et al., 2009;
Mitchell et al., 2009) (Fig. 1C, right panel). In contrast, the protein
level of NTB-A remained stable, altogether indicating that Vpu‘s
activity on NTB-A appears to be mechanistically distinct from
the Vpu induced degradation of CD4 (Binette et al., 2007; Chen
et al., 1993; Magadan et al., 2010; Willey et al., 1992) or thedownregulation of cell surface tetherin (Neil et al., 2008; Shah et al.,
2010; Van Damme et al., 2008).
NTB-A is not complexly glycosylated in the presence of Vpu
To study the effect of Vpu on the glycosylation pattern of NTB-A
in more detail, we used Endoglycosidase H (Endo H) to remove high
mannose oligosaccharides that are attached during core glycosyla-
tion of newly synthesized proteins in the ER. Parallel cultures of
293T cells were cotransfected with pNTB-A-2 and AU1-tagged wt
Vpu. Pulse-chase experiments were conducted as described in
Fig. 1B. Half of the immunoprecipitated NTB-A was treated with
Endo H, separated by SDS-PAGE, and analyzed by autoradiography.
Similar to the results in Fig. 1, in the absence of Vpu the 50 kDa
version of NTB-A was converted into the 60 kDa version within
approximately 30 min of chase (Fig. 2B), a process that did not occur
in the presence of Vpu (Fig. 2A, C left panel). Treatment with Endo H
revealed that NTB-A remains completely Endo H sensitive through-
out the chase period in the presence of Vpu, suggesting that Vpu
most likely interferes with the transport of NTB-A through the
secretory pathway (Fig. 2A, C right panel). In contrast, NTB-A
became Endo H resistant in the absence of Vpu after approximately
30 min of chase, a time that is usually required for the formation of
complex/hybrid-type glycosylated proteins in the secretory pathway
(Fullekrug et al., 1999) (Fig. 2B, C right panel). In consistency with
the results shown in Fig. 1, the 50 kDa as well as the completely
deglycosylated version of NTB-A remain stable in the presence of
Vpu. Thus, these results further support our notion that in contrast
to tetherin and CD4, Vpu does not affect the half life of NTB-A, but
rather affects its glycosylation pattern.
The Vpu-mediated changes in the glycosylation pattern of NTB-A
correlate with a decreased localization of NTB-A at the cell surface
In order to analyze whether the Vpu induced downregulation
of cell surface NTB-A correlates with the ability of Vpu to affect
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were performed. HeLa cells were transfected with pNTB-A-2 and
an expression plasmid for AU1-tagged wt Vpu. 24 h post transfec-
tion cell surface proteins were biotinylated with Sulfo-NHS-LC-
biotin. Cells were subsequently lysed and biotinylated proteins
were immunoprecipitated with immobilized Streptavidin, sepa-
rated by SDS-PAGE and analyzed by Western blot. NTB-A was
recovered with Streptavidin, indicating that it was present at the
cell surface in the absence of Vpu (Fig. 3A, lane 4), while in the
presence of Vpu, the amount of cell surface NTB-A was signiﬁ-
cantly decreased (Fig. 3A, lane 6, C). Interestingly, the enrichment
of cell membrane exposed NTB-A by Streptavidin pull-down
reveals that the high mannose as well as the mature form of
NTB-A localize at the cell surface (Fig. 3A, lane 6). This might
indicate that Vpu does not affect NTB-A, once it has reached the
plasma membrane (Fig. 3A). The control protein, ribosomal P
antigen 2 (RP2), which localizes exclusively in the cytoplasm, was
not detectable after immunoprecipitation, while as another con-
trol the Transferrin receptor (TfR) localized at the cell surfaceFig. 3. Cell surface biotinylation analysis of NTB-A in the presence or absence of
wt Vpu. HeLa cells were cotransfected with either pNTB-A-2 or AU1-tagged wt
Vpu. 24 h post transfection cell surface-expressed proteins were biotinylated.
Upon cell lysis, biotinylated proteins were captured with immobilized streptavi-
din, separated by SDS-PAGE and analyzed by Western blot. NTB-A and wt Vpu
were detected, using anti-NTB-A and polyclonal anti-Vpu antibodies. As positive
control the Transferrin receptor and as negative control the ribosomal P antigen
2 were detected, using anti-Transferrin and anti-ribosomal P antigen antibodies.
(A) Cell surface proteins after immunoprecipitation with Streptavidin. (B) Western
blot control of whole cell lysates. (C) Quantiﬁcation of relative NTB-A surface
expression (***pr0.05, student’s t-test). Bars represent mean7SD from three
independent experiments.(Fig. 3A). Consistent with the pulse-chase data, also in the steady
state situation as measured by Western blot revealed that Vpu
induces changes in the glycosylation pattern of NTB-A (Fig. 3B).
Similar results were obtained in transfected 293T cells (data not
shown). Thus, we could show that Vpu affects the glycosylation
pattern of NTB-A (Fig. 3B), and that this phenomenon is asso-
ciated with the ability of Vpu to inhibit the transport of newly
synthesized NTB-A molecules to the cell surface.
Vpu delays the anterograde transport of newly synthesized NTB-A
Having provided biochemical evidence for reduced cell surface
localization of NTB-A in the presence of Vpu, we next wanted to
analyze the Vpu mediated effect on the transport of NTB-A to the
cell surface by immunoﬂuorescence in more detail. We adopted
a microinjection approach, which was recently developed for
the analysis of the anterograde transport of de novo expressed
tetherin by confocal microscopy (Schmidt et al., 2011). To this end,
expression plasmids were microinjected into the nuclei of TZM-bl
cells and protein expression or localization was analyzed at
various time points post-injection. In the absence of Vpu, newly
synthesized NTB-A was efﬁciently transported to the cell surface
(over 25% and 80% of cells with detectable plasma membrane
NTB-A at 2 h and 6 h post- injection, respectively (Fig. 4A)).
Vpu signiﬁcantly reduced such anterograde transport of newly
synthesized NTB-A (only approximately 20% of cells with detect-
able plasma membrane NTB-A at 6 h post- injection (Fig. 4A,
NTB-A plasmamembrane localization 6 h post injection in absence
vs. presence of Vpu p¼r0.05)) and appeared to partially coloca-
lize with NTB-A in a perinuclear compartment. This interference of
NTB-A anterograde transport by Vpu represents a delay rather
than a block of transport, since the plasma membrane localization
of NTB-A continued to increase at later time points post- injection
(data not shown). These effects are distinct from the effect Vpu
exerts on the anterograde transport of tetherin, where Vpu
imposes a complete transport block that even remains stable over
an extended period of time (Fig. 4B) (Dube et al., 2009; Schmidt
et al., 2011). Moreover, Vpu-mediated trapping of tetherin in the
TGN results in a concentration of tetherin in a deﬁned subcellular
compartment that persists over time. Similar colocalization in a
deﬁned perinuclear compartment was observed for NTB-A and
Vpu 1 h post- injection. At later time points Vpu did not entirely
block the transport of NTB-A to the cell surface and the localization
of NTB-A appeared to be more diffuse. In summary, these results
suggest that Vpu slows down, but does not fully block, the
anterograde transport of newly synthesized NTB-A.
Increased colocalization of NTB-A within the Golgi-compartment
in the presence of wt Vpu
Since Vpu affects glycosylation of NTB-A, we speculated that
the anterograde transport of NTB-A is delayed at the level of the
Golgi-apparatus. Therefore, we assessed colocalization of the
galactosyltransferase-CFP fusion protein (GalT-CFP) (Rocks et al.,
2010) and NTB-A in wt Vpu expressing HeLa cells in comparison
to cells expressing only GFP or the truncated mutant Vpu D23,
which does not contain a-helix 2 and is preferably expressed at
the plasma membrane while its localization in the TGN is reduced
(Dube et al., 2009; Pacyniak et al., 2005) (Fig. 5). Images were
quantiﬁed by measuring the absolute percentage of pixels in the
Golgi (GalT-CFP) that colocalize with NTB-A. Analyses of 195 cells
revealed increased localization of NTB-A within the Golgi-
compartment when wt Vpu was expressed (13.00%, n¼80) in
comparison to cells transfected only with GFP (6.936%, n¼59) or
the Vpu D23 mutant (9.550%, n¼56) (Fig. 5). Importantly, the
observed differences were statistically highly signiﬁcant (po0.01)
Fig. 4. Vpu delays the anterograde transport of newly synthesized NTB-A to the cell surface. The nuclei of TZM-bl cells, grown on coverslips, were co-microinjected with
expression plasmids for HA-tagged NTB-A (A) or Tetherin-HA (intHA-Tetherin) (B) and vectors encoding GFP or Vpu.GFP. Subsequently, cells were cultivated for 1, 2, or 6 h
and then ﬁxed, permeabilized and stained with an anti-HA mAb followed by an Alexa 568-conjugated secondary Ab (red staining) to detect newly synthesized HA-NTB-A
or intHA-Tetherin. Shown are representative microphotographs with indicated cell circumferences (upper panels). Scale bars: 10 mm. Cells were categorized into those with
clear plasma membrane in addition to intracellular staining and cells with an exclusively intracellular staining of HA-NTB-A (A) or intHA-Tetherin (B). Histogram bars
(lower panels) depicting the relative percentage of cells with detectable plasma membrane staining for the indicated time points post microinjection. Shown are mean
values with indicated standard deviation from three independent experiments with a total of at least 150 cells analyzed per plasmid combination (n.s.¼non signiﬁcant.
***; pr0.05, student’s t-test).
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with NTB-A trafﬁcking by slowing down its passage through the
Golgi-apparatus.
While the CK-2 phosphorylation sites are dispensable, the second
a-helix of Vpu is critical to affect the glycosylation pattern and
surface expression of NTB-A
To investigate the importance of the CK-2 phosphorylation
sites and the second a-helix in the cytoplasmic domain for
the Vpu-mediated effect on the glycosylation pattern and surfaceexpression of NTB-A, a number of mutants were analyzed (Fig. 6A).
293T cells were cotransfected with either pNTB-A-2 and an
expression plasmid for AU1-tagged wt Vpu, or mutants thereof.
24 h post transfection cells were lysed and the soluble protein
fraction was analyzed by Western blot (Fig. 6B, D). The steady
state situation reveals that the Vpu m26 mutant as well as the
C-terminal deletion mutant Vpu D9 were capable of inducing the
same changes in the glycosylation pattern of NTB-A as observed
with wt Vpu (Fig. 6B). Furthermore, growing truncations of the
second a-helix impeded Vpus ability to interfere with NTB-A
glycosylation (Fig. 6D). The C-terminal deletion mutant Vpu D23
Fig. 5. Colocalization of NTB-A within the Golgi-compartment. HeLa cells, grown on cover slips, were transfected with plasmids expressing GFP as a control, Vpu or Vpu
D23 co-expressing GFP via an IRES element. Cells were cotransfected with NTB-A and the GalT-CFP fusion protein as a Golgi marker (blue). Forty-eight hours later cells
were ﬁxed and NTB-A (shown in red) was stained by immunoﬂuorescence. Transfected cells were identiﬁed by GFP expression and colocalization of Golgi (GalT-CFP) and
NTB-A was quantiﬁed by the absolute percentage of GalT-CFP pixels which stain also positive for NTB-A using Bitplane Imaris V6.4.2 image analysis software. Values for a
total of 195 analyzed cells were plotted and assessed for statistical signiﬁcance by using the GrapPad Prism V5.0 software package. Scale bars: 5 mm.
Fig. 6. The ability of wt Vpu and Vpu mutants to affect the glycosylation pattern and surface expression of NTB-A. (A) Schematic representation of wt Vpu or the Vpu
mutants m26-, D9-, D14- and D23. (B) 293 T cells were cotransfected with either pNTB-A-2 and wt Vpu, m26, D9 or D23 mutant. 24 h post transfection cells were lysed and
analyzed by Western blot, using anti-NTB-A, anti-Vpu and as loading control anti-ß-actin antibodies. The ratio of 60kDa/50kDa NTB-A is given on the right. Bars represent
mean7SD from three independent experiments. (C) Summary of relative NTB-A surface expression. Bars represent mean7SD from three independent experiments. HeLa
cells were cotransfected with either pNTB-A-2 and AU1-tagged wt Vpu, Vpu m26 or Vpu D23. 24 h post transfection cells were harvested and stained for surface NTB-A,
using a monoclonal NTB-A-speciﬁc antibody and analyzed by ﬂow cytometry. In addition, cells were lysed and analyzed by Western blot, using anti-Vpu or anti-ß-actin
antibodies, which is given below. (D) 293T cells were cotransfected with either pNTB-A-2 and wt Vpu, D14 or D23 mutant. 24 h post transfection cells were lysed and
analyzed by Western blot, using anti-NTB-A, anti-Vpu and as loading control anti-ß-actin antibodies. The ratio of 60 kDa/50 kDa NTB-A is given on the right.
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(Fig. 6B, D), indicating that this structural domain of Vpu might
be imported for the effect on NTB-A. To further unravel the
importance of the second a-helix in the cytoplasmic domain of
Vpu to affect the glycosylation pattern of NTB-A, we investigated
the Vpu D14 mutant, containing half of Vpus second a-helix.
This mutant has a decreased localization in the TGN similar to the
Vpu D23 mutant (Dube et al., 2009). Interestingly, the Vpu D14
mutant had an intermediate effect on the glycosylation pattern ofNTB-A (Fig. 6D), further suggesting that the second a-helix in the
cytoplasmic domain of Vpu is critical for Vpus effect on NTB-A
glycosylation. Moreover, the expression levels of all Vpu proteins
were comparable (Fig. 6B, D).
In order to analyze whether the Vpu-mediated effect on the
glycosylation pattern of NTB-A again correlates with a decreased
surface expression of NTB-A, HeLa cells were cotransfected with
either pNTB-A-2 and an expression plasmid for AU1-tagged wt Vpu,
Vpu m26 or Vpu D23 along with GFP translated via an internal
Fig. 7. Conﬁnement of Vpu in the ER abrogates its ability to affect the glycosylation pattern and surface expression of NTB-A. (A) Parallel cultures of 293T cells were
cotransfected with either pNTB-A-2 alone or together with AU1-tagged wt Vpu, the Vpu D23 or the VpuA18H and Vpu-KKDQ mutants. 24 h post transfection cells were
pulse labeled with [35S]methionine for 7 min and chased for up to 2 h. NTB-A molecules were immunoprecipitated with an anti-NTB-A antibody, analyzed by SDS-PAGE
and autoradiography. Quantiﬁcation of the kinetics on NTB-A glycosylation is given below. (B) CD4þ T cells were infected with either HIV-1 NL4-3 Vpu Del-1, HIV-1 NL4-3
wt, HIV-1 NL4-3 Vpu A18H or HIV-1 NL4-3 Vpu D23 and 7 days after infection the cells were harvested and stained for surface NTB-A, using a NTB-A-speciﬁc antibody.
Afterwards the cells were stained intracellularly for HIV-1 p24 antigen, using anti-p24-FITC speciﬁc antibody and analyzed by ﬂow cytometry. In addition, cells were lysed
and analyzed by Western blot, using anti-Vpu, anti-CA or anti-ß-actin antibodies. Quantiﬁcation of the relative surface expression of NTB-A is given below. Bars represent
mean7SD from three independent experiments.
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post transfection cells were harvested and stained for surface NTB-A,
using a speciﬁc NTB-A antibody and analyzed by ﬂow cytometry. The
surface expression of NTB-A in Vpu positive cells was calculated as
mean ﬂuorescence intensity (MFI) of NTB-A expression in GFP
positive cells, demonstrating that wt Vpu as well as Vpu m26
downregulate cell surface NTB-A (Fig. 6C). As expected, the Vpu
D23 mutant only marginally downregulated cell surface NTB-A.
Taken together, while the CK-2 phosphorylation sites of Vpu are
dispensable, the second a-helix 2 in the cytoplasmic domain of Vpu
seems to be required to affect the glycosylation pattern of NTB-A and
to induce downregulation of cell surface NTB-A.Vpu affects the glycosylation pattern and surface expression of NTB-A
within post-ER compartments
To investigate whether localization of Vpu in the ER is required
to affect the glycosylation pattern of NTB-A, pulse-chase analyses
with the ER-trapped mutants Vpu A18H and Vpu-KKDQ were
performed. It was previously shown that mutation of Ala-18 to
His (A18H) results in an abnormal conﬁnement of Vpu in the ER,
similarly to the Vpu-KKDQ mutant that contains an ER retention
signal at the C-terminus (Bolduan et al., 2011; Shikano and Li, 2003;
Skasko et al., 2011; Vigan and Neil, 2011). Parallel cultures of
293T cells were cotransfected with pNTB-A-2 and expression
Fig. 8. The effect of BFA on the glycosylation pattern of NTB-A. Parallel cultures of
293 T cells were cotransfected with either pNTB-A-2 or AU1-tagged wt Vpu. 24 h
post transfection half of each culture was incubated in RPMI 1640-FBS in the
absence or presence of 2 mg of BFA per ml. Cells were then labeled for 7 min with
[35S]methionine, chased for up to 2 h, separated by SDS-PAGE and analyzed by
autoradiography. All steps were performed in the presence of 2 mg of BFA per ml.
Quantiﬁcation of the kinetics of NTB-A isoform 2 glycosylation is given below. Bars
represent mean7SD from three independent experiments.
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KKDQ mutant. 24 h post transfection cells were pulse labeled
with [35S]methionine and chased for up to 2 h. After cell lysis,
NTB-A molecules were immunoprecipitated with an anti-NTB-A
antibody and the soluble protein fraction was analyzed by SDS-
PAGE and autoradiography. As shown in Fig. 7A, only wt Vpu
efﬁciently modulated the glycosylation pattern of NTB-A, while
the mutants Vpu D23, Vpu A18H and Vpu-KKDQ exhibit an
attenuated activity on NTB-A glycosylation (Fig. 7A), altogether
indicating that ER conﬁnement of Vpu abrogates its ability to
affect the glycosylation pattern of NTB-A.
Next, we analyzed whether the Vpu mutants A18H or D23 are
capable of inducing downregulation of endogenous cell surface
NTB-A (Fig. 7B). Thus, primary CD4þ T cells were infected with
either the Vpu deletion mutant HIV-1 NL4-3 Vpu Del-1 and HIV-1
NL4-3 wt, HIV-1 NL4-3 Vpu A18H or HIV-1 NL4-3 Vpu D23, and
surface expression of NTB-A was analyzed by ﬂow cytometry.
As expected, HIV-1 NL4-3 wt was capable of inducing down-
regulation of NTB-A from the cell surface (Fig. 7B). However, the
Vpu deletion mutant HIV-1 NL4-3 Vpu Del-1 and the Vpu mutants
HIV-1 NL4-3 Vpu A18H and HIV-1 NL4-3 Vpu D23 lost their
ability to induce efﬁcient downregulation of cell surface NTB-A
(Fig. 7B). These results suggest that localization of Vpu within
post-ER compartments is required to induce downregulation of
NTB-A from the cell surface.
Conﬁnement of NTB-A in the ER prevents the formation of complex/
hybrid-type glycosylated NTB-A
Next, we investigated the effect of BFA on the glycosylation
pattern of NTB-A by pulse-chase analyses. BFA is a fungal meta-
bolite which blocks protein trafﬁcking from the ER to the Golgi
complex and interrupts posttranslational processing occurring in
the TGN (Misumi et al., 1986). Hence, parallel cultures of 293T
cells were transfected with either, pNTB-A-2 together with an
expression plasmid for AU1-tagged wt Vpu, or an empty vector
control. 24 h post transfection half of the cells were incubated for
3 h with BFA or left untreated. Cells were pulse labeled with
[35S]methionine and chased for up to 2 h. After cell lysis, NTB-A
was immunoprecipitated and analyzed by SDS-PAGE and auto-
radiography. In the absence of BFA and Vpu, the 50 kDa version of
NTB-A was rapidly converted into the 60 kDa version within the
standard, after approximately 30 min of chase. This conversion
was completely abolished in the presence of BFA (Fig. 8), indicating
that Vpu governs a mechanism that, at least in its outcome,
is similar to the effect induced by BFA.
Tunicamycin and Glycopeptidase F (PNGaseF) completely
deglycosylate NTB-A
We next analyzed the glycosylation pattern of NTB-A, using
the N-linked glycosylation inhibitor Tunicamycin. Furthermore,
we used PNGaseF, an enzyme that catalyzes the complete
removal of N-linked oligosaccharide chains from glycoproteins
(Norris et al., 1994). 293T cells were transfected with pNTB-A-2
and 4 h before cell lysis, cells were incubated with increasing
amounts of Tunicamycin. Tunicamycin is a nucleoside antibiotic
which inhibits N-linked glycosylation (Elbein, 1987; Tkacz
and Lampen, 1975). Increasing concentrations of Tunicamycin
induced the occurrence of a complete deglycosylated version of
NTB-A and of a band with an apparent molecular weight of
approximately 37 kDa (Fig. 9A). Furthermore, the glycosylation
pattern of NTB-A was analyzed via PNGaseF digestion. To this end,
293T cells were transfected with pNTB-A-2 and an expression
plasmid for wt Vpu or the Vpu D23 mutant and left untreated or
treated with PNGaseF, respectively. 24 h post transfection thecells were lysed and subsequently treated with 500 U PNGaseF,
separated by SDS-PAGE and analyzed by Western blot. In the
absence of PNGaseF, wt Vpu was capable to induce changes in the
glycosylation pattern of NTB-A (Fig. 9B). Consistently, this effect
was not observed when the Vpu D23 mutant was expressed
(Fig. 9B), which was also conﬁrmed by previous pulse chase data
(Fig. 7A). After digestion with PNGaseF, only the deglycosylated
form of NTB-A was detectable (Fig. 9B). As expected, no changes
in the steady state protein level of NTB-A were observed (Fig. 9B).
Thus, Vpu did not inﬂuence the stability of NTB-A, but selectively
inhibited the formation of the complex/hybrid-type glycosylated
NTB-A.
With the exception of HIV-1 group N, Vpu-mediated
downmodulation of NTB-A is highly conserved among diverse
primate lentiviruses
To examine to which extent the effect of Vpu on NTB-A is
conserved among primate lentiviral Vpus, we analyzed the ability
of various Vpu alleles of HIV-1 and SIV to affect the glycosylation
pattern and surface expression of NTB-A. 293T cells were cotrans-
fected with either pNTB-A-2 and expression plasmids for AU1-
tagged Vpu derived from HIV-1 M NL4-3, SIVgsn 166, SIVcpz
EK505, SIVgor CP2139 or HIV-1 N CK1.62. 24 h post transfection
cells were lysed and analyzed by Western blot (Fig. 10A). The
steady state situation revealed that Vpus derived from HIV-1 M
NL4-3, SIVgsn 166, SIVcpz EK505, and SIVgor CP2139 are capable
of inducing changes in the glycosylation pattern of NTB-A
(Fig. 10A). Only Vpu derived from HIV-1 N exhibits an attenuated
activity on NTB-A glycosylation. To investigate whether the Vpu-
mediated effect on NTB-A glycosylation correlates with a
decreased localization of NTB-A at the cell surface, HeLa cells
were cotransfected with either pNTB-A-2 together with AU1-
tagged Vpu derived from HIV-1 M NL4-3, SIVgsn 166, SIVcpz
EK505, SIVgor CP2139 or HIV-1 N CK1.62. 24 h post transfection
cells were harvested and stained for surface NTB-A, using a
speciﬁc NTB-A antibody and analyzed by ﬂow cytometry
(Fig. 10B). In addition, cells were lysed, separated by SDS-PAGE
and analyzed by Western blot, demonstrating that the expression
levels of all Vpu proteins were comparable (Fig. 10B). Vpu
Fig. 9. Analysis of the glycosylation pattern of NTB-A after treatment with Tunicamycin and PNGaseF. (A) Titration of Tunicamycin in the presence of NTB-A. 293 T cells
were transfected with pNTB-A-2 and 4 h before cell lysis, cells were treated with increasing amounts of Tunicamycin and analyzed by Western blot, using anti-NTB-A and
as loading control anti-ß-actin antibodies. (B) PNGaseF-digestion of NTB-A. 293T cells were cotransfected with either pNTB-A-2 and AU1-tagged wt Vpu or the D23 mutant,
and then either treated with PNGaseF or left untreated. 24 h post transfection, the cells were lyzed and the soluble fraction was digested with PNGaseF and analyzed by
Western blot, using anti-NTB-A-, anti-Vpu- and as loading control anti-ß-actin antibodies. The relative amount of 37 kDa NTB-A is given on the right. Bars represent
mean7SD from three independent experiments.
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SIVgor CP2139 are capable of inducing downregulation of cell
surface NTB-A. However, the Vpu protein derived from HIV-1 N
lost its ability to induce efﬁcient downregulation of cell surface
NTB-A (Fig. 10B). This observation ﬁts with the results obtained in
Fig. 10A. Thus, we conclude that the Vpu-mediated effect on NTB-
A glycosylation is conserved among Vpu proteins of HIV-1 and
SIV, and this phenomenon is associated with a decreased localiza-
tion of NTB-A on the cell surface.Discussion
In this study, we demonstrate that HIV-1 Vpu blocks the
intracellular transport and thus the glycosylation pattern of the
coactivating receptor NTB-A, which facilitates NK cell killing of
virus infected cells (Bottino et al., 2001; Shah et al., 2010). This is
particularly important, because HIV-1 Nef downregulates the
inhibitory ligands HLA-A and -B, however not HLA-C and -E from
the cell surface (Cohen et al., 1999). Further, another accessory
protein HIV-1 Vpr upregulates the activating NKG2D ligands
(ULBP-1, ULBP-2) (Ward et al., 2009), altogether increasing the
susceptibility of HIV-1 infected cells for lysis by NK cells.
By pulse-chase kinetic analyses it was shown that Vpu prevents
the formation of the complex/hybrid-type glycosylated version
of NTB-A isoform 2 (Fig. 1A). Therefore, we speculated that
Vpu interferes with the correct transport of NTB-A through
the secretory pathway. Moreover, the glycosylation pattern ofNTB-A isoform 1, which contains an alanine insertion at amino
acid position 266, was also affected by Vpu similar to the NTB-A
isoform 2 (Fig. 1B). Interestingly, the expression level of NTB-A
isoform 1 (Ly108-1) in lymphocytes of lupus-prone mice is higher
compared to that of NTB-A isoform 2 (Ly108-2), which correlated
with an increased T cell antigen receptor-mediated calcium ﬂuxes
in vitro (Zhong and Veillette, 2008).
However, in contrast to NTB-A, Vpu has no effect on the
glycosylation pattern of tetherin, but induces its degradation
(Fig. 1C), suggesting that the effect of Vpu on the glycosylation
pattern of NTB-A is mechanistically distinct from the Vpu induced
downmodulation of tetherin.
In the absence of Vpu and upon treatment of NTB-A with Endo
H, the mature form of NTB-A remains Endo H resistant after
30 min of chase (Fig. 2B), implying that the 60 kDa version of
NTB-A most likely represents the complex/hybrid-type glycosy-
lated version of NTB-A. In contrast, NTB-A remains Endo H
sensitive (Fig. 2A) in the presence of Vpu, indicating that the
50 kDa version of NTB-A represents the high mannose form of
NTB-A. However, it should be noted that Vpu does obviously not
destabilize the deglycosylated or high mannose version of NTB-A,
which is consistent with previous studies providing ﬁrst evidence
that Vpu does not alter the steady state protein level of NTB-A
(Shah et al., 2010).
Next, it was investigated whether the Vpu-mediated effect on
NTB-A glycosylation correlates with the ability of Vpu to down-
regulate NTB-A from the cell surface. In the presence of wt Vpu,
a decreased localization of NTB-A at the cell surface was
Fig. 10. Effect of lentiviral Vpu proteins on the glycosylation pattern and cell surface expression of NTB-A. (A) 293 T cells were cotransfected with either pNTB-A-2 and
AU1-tagged Vpu of HIV-1 M NL4-3, SIVgsn 166, SIVcpz EK505, SIVgor CP2139 or HIV-1 N CK1.62. 24 h post transfection cells were lysed and analyzed by Western blot,
using anti-NTB-A, anti-Vpu and as loading control anti-ß-actin antibodies. The ratio of 60 kDa/50 kDa NTB-A is given on the right side. (B) HeLa cells were cotransfected
with either pNTB-A-2 and AU1-tagged Vpu of HIV-1 M NL4-3, SIVgsn 166, SIVcpz EK505, SIVgor CP2139 or HIV-1 N CK1.62. 24 h post transfection cells were harvested and
stained for surface NTB-A, using a monoclonal NTB-A-speciﬁc antibody and analyzed by ﬂow cytometry. Summary of relative NTB-A surface expression is given on the left
side. Bars represent mean7SD from three independent experiments. In addition, cells were lysed and analyzed by Western blot, using anti-AU1 and anti-ß-actin
antibodies, which is given on the right side.
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transport of NTB-A through the secretory pathway by disturbing
its correct glycosylation.
Furthermore, a microinjection approach revealed that the
anterograde transport of newly synthesized NTB-A is delayed in
the presence of wt Vpu (Fig. 4A). This phenomenon ﬁts with the
observation that Vpu induces changes in the glycosylation pattern
of NTB-A. Moreover, as control the anterograde transport of
newly synthesized tetherin molecules is completely blocked in
the presence of wt Vpu (Fig. 4B).
Indeed, quantitative colocalization analysis exploiting a
Galactosyltransferase-CFP fusion protein as Golgi-marker (Rocks
et al., 2010) revealed that NTB-A accumulated in the Golgi-
apparatus in Vpu-expressing cells (Fig. 5). Consistent with the
delayed, but not abrogated transport of NTB-A to the plasma
membrane in the presence of Vpu, NTB-A was not completely
retained in the Golgi complex. Furthermore, the Vpu D23 mutant
showed an intermediate phenotype (Fig. 5), which ﬁts well with
the strongly reduced ability of this mutant to remove NTB-A from
the cell surface (Fig. 6C). These results suggest that the post-ER
interference of Vpu with NTB-A trafﬁcking occurs at the site of the
Golgi-apparatus, and therefore, represents a plausible mode of
action how Vpu might block cell surface expression of cellular
receptors.
In addition, we investigated whether CK-2 phosphorylation of
Vpu is required to affect the glycosylation pattern of NTB-A
(Fig. 6). The Vpu m26 mutant contains an exchange of two serine
residues by asparagine at amino acid positions 52 and 56, whichare essential to induce CD4 degradation by the ubiquitin-
proteasome pathway (Binette et al., 2007; Magadan et al., 2010;
Schubert et al., 1998). It was previously demonstrated that the
Vpu m26 mutant is capable of inducing downregulation of NTB-A
from the cell surface (Shah et al., 2010). In consistency, we show
that the Vpu m26 mutant affected the glycosylation pattern and
surface expression of NTB-A in a wild type manner (Fig. 6B, C),
further supporting our notion that this phenomenon is mechan-
istically distinct from the Vpu induced inhibition of CD4 and
tetherin (Schindler et al., 2010). However, the C-terminal deletion
mutant Vpu D9, which was shown to have only marginal effects
on the subcellular localization of the protein (Dube et al., 2009),
also has no inﬂuence on the glycosylation pattern and surface
expression of NTB-A (Fig. 6B, C), suggesting that the last nine
amino acids of Vpu‘s C-terminus are not involved in this mechan-
ism. As shown previously, the Vpu D23 mutant, which does not
contain helix 2, but still maintained the CK-2 phophorylation
sites, has a signiﬁcantly decreased localization in the TGN (Dube
et al., 2009; Pacyniak et al., 2005). The Vpu D23 mutant was
shown to be incapable to enhance virion release in the presence
of tetherin (Dube et al., 2009) and to induce degradation of CD4
(data not shown). Interestingly, this mutant is attenuated in its
ability to efﬁciently induce downregulation of cell surface NTB-A
and to interfere with NTB-A glycosylation (Fig. 6B, C), indicating
that the second a-helix and/or the localization of Vpu in the TGN
are required for the Vpu-mediated effect on NTB-A.
We could also demonstrate that the two ER-trapped mutants,
Vpu A18H and Vpu-KKDQ, cannot affect the glycosylation pattern
S. Bolduan et al. / Virology 440 (2013) 190–203200of NTB-A (Fig. 7A), furthermore supporting the notion that the
effect of Vpu on NTB-A occurs within post-ER compartments.
Moreover, we show that the Vpu mutants HIV-1 NL4-3 A18H
and HIV-1 NL4-3 D23 were strongly attenuated to induce down-
regulation of NTB-A in primary CD4þ T cells (Fig. 7B), again
indicating that localization of Vpu in post-ER compartments is
required for the effect of Vpu on the glycosylation pattern and
surface expression of NTB-A.
To investigate whether the Vpu-mediated effect on NTB-A
glycosylation and the ability of Vpu to induce downregulation of
cell surface NTB-A are conserved among primate lentiviral Vpus,
we analyzed Vpu alleles from diverse HIV-1 and SIV strains
(Fig. 10). Vpu proteins derived from HIV-1 M and its precursors
SIVgsn, SIVcpz and SIVgor are capable of inducing changes in the
glycosylation pattern of NTB-A (Fig. 10A). This phenomenon
correlates with a decreased localization of NTB-A at the cell
surface (Fig. 10B), indicating that the effect of Vpu on NTB-A
is highly conserved among primate lentiviral Vpu proteins.
However, Vpu derived from HIV-1 N has no inﬂuence on the
glycosylation pattern of NTB-A and cannot induce efﬁcient down-
regulation of cell surface NTB-A (Fig. 10A, B), suggesting that Vpu
derived from HIV-1 N lost its anti-NTB-A activity.
In regard to the capacity of Vpu to retain glycoproteins in the
exocytotic pathway, it was previously reported that Vpu is able to
trap the HIV-1 glycoprotein gp120 and VSV-G in the ER/Golgi
complex (Vincent and Abdul Jabbar, 1995). However, in contrast
to the phenomenon we described herein, the authors reported
that their effect requires the CK-2 phosphorylation of Vpu
(Vincent and Abdul Jabbar, 1995). Currently, it is not clear
whether our observation is speciﬁc for NTB-A or also applies for
other host cell glycoproteins. Clearly, the effect of Vpu on viral
glycoproteins (Vincent and Abdul Jabbar, 1995), which require
the CK-2 phosphorylation, is part of a different mechanism that
would be more related to Vpu‘s activity on CD4. Independent of
this unresolved question, it is obvious that Vpu exerts different
inhibitory activities within the secretory pathway (Dube et al.,
2010; Matusali et al., 2012; Shah et al., 2010; Vincent and Abdul
Jabbar, 1995).Conclusion
Taken together, in this study we demonstrate that Vpu inter-
feres with the anterograde transport of NTB-A at the site of the
Golgi-compartment and induces changes in the glycosylation
pattern of NTB-A by a post-ER mechanism. Moreover, with the
exception of Vpu derived from HIV-1 group N, the Vpu-mediated
effect on the glycosylation pattern and surface expression of NTB-A
is conserved among lentiviral Vpu proteins of HIV-1 and SIV.
This activity of Vpu might contribute to the detrimental effect of
Vpu on other host cell factors.Materials and methods
Site-directed mutagenesis and plasmid constructions
All plasmids containing HIV-1 sequences are derivatives of the
infectious molecular clone pNL4-3 (Adachi et al., 1986). The HIV-1
NL4-3 wt and HIV-1 Vpu Del-1 expression plasmids were described
elsewhere (Klimkait et al., 1990). Mutation of the HIV-1 NL4-3 Vpu
A18H and HIV-1 NL4-3 Vpu D23 plasmids were introduced by site
directed mutagenesis (Quick change Kit, Stratagene), using oligonu-
cleotides, containing indicated changes. For cloning of the pCG-HIV-
1 M NL4-3 Vpu D9-, pCG-HIV-1 M NL4-3 Vpu D23- and pCG-HIV-1
M NL4-3 Vpu-KKDQ-AU1-IRES-GFP mutants, the mutations weregenerated by PCR into the previously described pCG-IRES-GFP
vector, expressing GFP from a bicistronic mRNA (Sauter et al.,
2009; Schindler et al., 2003). The pCG-HIV-1 M NL4-3 wt Vpu-
AU1-IRES-GFP, pCG-HIV-1 M NL4-3 Vpu A18H-AU1-IRES-GFP,
pCG-HIV-1 M NL4-3 Vpu m26-IRES-GFP, pCG-nef STOP-IRES-GFP,
pCG-SIVgsn 166 Vpu-AU1-IRES-GFP, pCG-SIVcpz EK505 Vpu-AU1-
IRES-GFP, pCG-SIVgor CP2139 Vpu-AU1-IRES-GFP and pCG-HIV-1 N
CK1.62 Vpu-AU1-IRES-GFP plasmids were described elsewhere
(Bolduan et al., 2011; Sauter et al., 2009; Schindler et al., 2003). To
generate the pcDNA3.3 TOPO-NTB-A isoform 2 (pNTB-A-2) expres-
sion plasmid, NTBA was ampliﬁed via PCR of the pCDONR223-
SLAMF6 plasmid (addgene), using primers (NTB-A FOR: 50 AAA CTC
GAG ATG TTG TGG CTG TTC 30 and NTB-A REV: 50 AAA GGT ACC TCA
CAA CAC GAC ATT 30) and subcloned in the pcDNA3.3 TOPO plasmid,
using the pCDNATM3.3-TOPOs TA Clonings Kit (Invitrogen), leading
to pcDNA3.3 TOPO-NTB-A isoform 2 (pNTB-A-2). NTB-A isoform
1 was ampliﬁed by PCR from pQCXIP-SLAM6, which was kindly
provided by Edward Barker (Rush University Medical Center, Chi-
cago). Restriction sites XbaI and MluI were added via the respective
primers (NTB-A FOR: 50 CGT CTA GAA TAT GTT GTG GCT GTT CCA
ATC 30 and NTB-A REV: 50 CTA CGC GTT ACA CGA CAT TGT CAA GGG
CAG 30) and the PCR product was subcloned into the CMV promoter
based expression vector pCG that directly expresses NTB-A isoform
1 together with GFP from a bicistronic mRNA (Schindler et al., 2003),
using standard techniques. The pCMV-Flag-Tetherin, Vpu-GFP,
pCFP-GalT and the HA-tagged tetherin expression vector were
described elsewhere (Banning et al., 2010; Bolduan et al., 2011;
Rocks et al., 2010; Schmidt et al., 2011).
Cell culture
HeLa and 293T cells were cultivated in Dulbecco’s modiﬁed
Eagle medium (DMEM) supplemented with 10% heat inactivated
fetal calf serum (FCS) and 2 mM L-glutamine, 100 U ml1 peni-
cillin and 100 mg ml1 streptomycin.
CD4þ T cells were maintained in RPMI 1640-FBS and were fed
by replacing 80% of the medium at 2-day intervals. CD4þ T cells
were stimulated for 2 days with phytohemagglutinin [1 mg/ml]
and Interleukin-2 [100 U/ml].
Western blot analysis
293T or HeLa cells were transiently transfected, using Lipo-
fectamine 2000TM (Invitrogen) according to the manufacturer’s
protocol. 24 h post transfection, cells were lysed in 0.5% NP-40
lysis buffer (150 mM NaCl, 50 mM Tris–HCl, 0.5% Nonidet P-40
and a protease inhibitor cocktail (Roche)). Cell lysates were
cleared by centrifugation at 10,000 rpm and 4 1C for 5 min.
NP-40 soluble proteins were separated in 12% SDS/PAA gels,
according to Laemmli (1970), transferred onto PVDF membranes
(GE Healthcare) and probed with speciﬁc antibodies, followed
by enhanced chemiluminescence detection. For internal controls,
blots were stripped and re-incubated with the appropriate
antibody.
Cell surface protein biotinylation
Cell surface proteins were biotinylated with EZ-Link Sulfo-
NHS-LC-biotin (Thermo scientiﬁc) according to the manufac-
turer’s protocol. Brieﬂy, HeLa cells were washed three times with
ice-cold phosphate-buffered saline (PBS), and primary amines of
the membrane proteins exposed to the exterior of the cells were
biotinylated with EZ-Link Sulfo-NHS-LC-biotin for 15 min at 4 1C.
The cells were washed and lysed, using 0.5% NP-40 lysis
buffer (150 mM NaCl, 50 mM Tris–HCl, 0.5% Nonidet P-40 and a
protease inhibitor cocktail (Roche)). Biotinylated proteins were
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Scientiﬁc Pierce). Precipitated material was washed four times
in 0.5% NP-40 buffer, separated in 12% SDS-PAA gel and analyzed
by Western blot, using polyclonal anti-Vpu antiserum (rabbit) for
detection of Vpu, anti-human NTB-A (BioLegend) for detection of
NTB-A, human anti-ribosomal P antibody (Immunosion, INC) to
detect ribosomal P antigen and mouse anti-Transferrin receptor
(Invitrogen) to detect the Transferrin receptor. Data analysis was
performed by using an Aida image analyzer (Raytest).
Metabolic labeling and immunoprecipitation
293T cells were cotransfected with either pNTB-A-2/pCG-NTB-
A isoform 1 and pCG-HIV-1 M NL4-3 wt Vpu-AU1-IRES-GFP or
Vpu mutants. 24 h post transfection, the cells were washed once
with PBS (10 mM phosphate buffer [pH 7.4], 100 mM NaCl), and
starved for 30 min in methionine- and cysteine-free RPMI 1640
medium (Sigma). Cells were pulse labeled with [35S]methionine
for 7 min at 37 1C. The medium was then removed and equal
aliquots were added to 1 ml of RPMI 1640-FBS for each time point
of the chase period and incubated at 37 1C. At the indicated time
points, cells were collected and stored at 80 1C. Cells were lysed,
using 0.5% NP-40 lysis buffer. Immunoprecipitations were incu-
bated for 3 h at 4 1C, using GammaBindTM Plus SepharoseTM (GE
Healthcare Bio-Science AB) coupled anti-NTB-A antibody (Bio
Legend). Immunoprecipitated proteins were washed, using Triton
wash buffer and solubilized by boiling in sample buffer contain-
ing 2% SDS, 1% 2-Mercaptoethanol, 1% glycerol, and 65 mM Tris
hydrochloride (pH 6.8) and separated by SDS-PAGE. Gels were
ﬁxed for 120 min by incubation in 50% methanol, 10% acetic acid
and 20% glycerol, rinsed with water and dried. Radioactive bands
were visualized by ﬂuorography. Quantitation of the radioactivity
of the bands was performed by using an Aida image analyzer.
In experiments involving BFA, cells were incubated for 3 h in
RPMI 1640-FBS, supplemented with BFA [2 mg/ml], with a com-
plete change of the medium after the ﬁrst 2 h. Cells were then
washed once in methionine- and cysteine-free RPMI 1640 med-
ium (Sigma) containing 2 mg of BFA per ml and preincubated for
30 min in 5 ml of the same medium. Subsequently, cells were
labeled for 7 min with [35S]methionine (200 [mCi/ml]) and chased
for up to 2 h. All steps were done in the presence of 2 mg of BFA
per ml. During the chase period, fresh BFA [2 mg/ml] was added
every 2 h.
In experiments involving Endo H, cells were incubated for
30 min at 37 1C in methionine and cysteine-free RPMI 1640
medium (Sigma), pulse labeled with [35S]methionine for 7 min
and chased for up to 2 h. After cell lysis, using 0.5% NP-40 lysis
buffer, NTB-A molecules were immunoprecipitated for 3 h at 4 1C,
using GammaBindTM Plus SepharoseTM (GE Healthcare Bio-
Science AB) coupled anti-NTB-A antibody (Bio Legend). Bead-
bound material was split and either treated with 100 U Endo H
(New England Biolabs) for 50 min at 37 1C or left untreated.
Samples were separated by SDS-PAGE and labeled proteins were
visualized via autoradiography.
In experiments involving tetherin, 293T cells were cotrans-
fected with either pCMV-Flag-Tetherin or pCG- wt Vpu-AU1-IRES-
GFP. 24 h post transfection cells were incubated for 30 min at
37 1C in methionine and cysteine-free RPMI 1640 medium
(Sigma), pulse labeled with [35S]methionine for 7 min at 37 1C
and chased for up to 2 h. After cell lysis, using RIPA buffer (50 mM
Tris–HCl pH 7.4, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium
deoxycholat, 0.1% Na-SDS, 5 mM EDTA, DNase, 1 mM PMSF and
complete protease inhibitor cocktail (Roche)), tetherin molecules
were immunoprecipitated for 3 h at 4 1C, using anti-Flag M2
afﬁnity matrix (Sigma). Samples were separated by SDS-PAGE
and labeled proteins were visualized via autoradiography.PNGaseF digestion
293T cells were cotransfected with either pNTB-A-2 and pCG-
HIV-1 M NL4-3 wt Vpu-AU1-IRES-GFP or the pCG-HIV-1 M NL4-3
Vpu D23-IRES-GFP mutant. 24 h post transfection the cells were
washed once with PBS and lysed, using 0.5% NP-40 lysis buffer.
For glycopeptidase F digestion, cells were adjusted to 50 mM
sodium phosphate [pH 7.5] and 1% NP-40, and incubated with
500 U of glycopeptidase F (New England Biolabs) for 30 min at
37 1C. The digested samples were separated by SDS-PAGE and
analyzed by Western blot, using polyclonal anti-Vpu antiserum
(rabbit), anti-human NTB-A (BioLegend) and as loading control
anti-ß-actin (Sigma) antibodies. Data analysis was performed by
using an Aida image analyzer (Raytest).
Tunicamycin treatment
293T cells were transfected with pNTB-A-2. Increasing
amounts of Tunicamycin (50–500 ng/ml) were added to 1 ml of
RPMI 1640-FBS 4 h before cell lysis. The cells were lysed, using
0.5% NP-40 lysis buffer, separated by SDS-PAGE and analyzed by
Western blot, using polyclonal anti-Vpu antiserum (rabbit), anti-
human NTB-A (BioLegend) and as loading control anti-ß-actin
(Sigma) antibodies.
HIV-1 infection of CD4þ T cells
CD4þ T cells were isolated from peripheral blood mononuclear
cells (Buffy-Coat from the Institute for Transfusion Medicine in
Suhl), which were prepared from gradient-isolated lymphocytes
of a healthy HIV-seronegative individual, using human CD4-
Micro-Beads (Miltenyi Biotec Inc.). For each infection, 5106
CD4þ T cells were stimulated for 2 days with phytohemagglutinin
[1 mg/ml] and Interleukin-2 [100 U/ml]. The cells were infected
with HIV-1 NL4-3 Vpu Del-1, HIV-1 NL4-3 wt, HIV-1 NL4-3 Vpu
D23 and HIV-1 NL4-3 Vpu A18H. 7 days after infection, cells were
analyzed by ﬂow cytometry. CD4þ T cells were maintained in
RPMI 1640-FBS and were fed by replacing 80% of the medium at
2-day intervals. Virus stocks were prepared in 293T cells trans-
fected with HIV-1 NL4-3 Vpu Del-1, HIV-1 NL4-3 wt, HIV-1 NL4-3
Vpu D23 and HIV-1 NL4-3 Vpu A18H plasmid DNA. Virus-
containing supernatants were centrifuged at 1000 g for 5 min.
Virions were puriﬁed by centrifugation through 20% sucrose at
20,000 g for 90 min.
Flow cytometric analysis of Vpu-mediated downregulation of NTB-A
HeLa cells were cotransfected with either pNTB-A-2 and pCG-
SIVgsn 166 Vpu-AU1-IRES-GFP, pCG-SIVcpz EK505 Vpu-AU1-IRES-
GFP, pCG-SIVgor CP2139 Vpu-AU1-IRES-GFP, pCG-HIV-1 N CK1.62
Vpu-AU1-IRES-GFP, pCG- HIV-1 M NL4-3 wt Vpu-AU1-IRES-GFP
or mutants. 24 h post transfection, the cells were harvested and
stained for surface NTB-A, using an anti-NTB-A antibody (Bio
Legend) and chicken anti-mouse Alexa647 conjugated secondary
antibody (Molecular Probes, Invitrogen). NTB-A surface expres-
sion on GFP positive cells was then analyzed in a FACS LSRII, using
FACSDiva software (BD Biosciences). Data analysis was performed
by using FCS Express V3 software (De Novo).
CD4þ T cells were infected with either HIV-1 NL4-3 Vpu Del-1,
HIV-1 NL4-3 wt or HIV-1 NL4-3 Vpu A18H. Seven days after
infection the cells were harvested and stained for surface NTB-A,
using a NTB-A-speciﬁc antibody (BioLegend) and chicken anti-
mouse Alexa647 conjugated secondary antibody (Molecular
Probes, Invitrogen). Afterwards the cells were stained intracellu-
larly for HIV-1 p24 antigen, using anti-KC57-FITC-speciﬁc anti-
body (COULTER CLONEs) and cell surface expression of NTB-A
S. Bolduan et al. / Virology 440 (2013) 190–203202was analyzed in a FACS LSRII, using FACSDiva software (BD
Biosciences). Data analysis was performed by using FCS Express
V3 software (De Novo).
NTB-A anterograde biosynthetic transport assay
TZM-bl cells, grown on coverslips, were microinjected into
their nuclei with an AIS 2 microinjection apparatus using pulled
borosilicate glass capillaries in principle as previously reported
(Schmidt et al., 2011). Plasmids encoding an HA-tagged tetherin
that carries an HA epitope tag at position 154 in the extracellular
domain (Tetherin-HAint) or HA-tagged NTB-A and GFP or
C-terminally GFP tagged Vpu, respectively, were mixed in H2O
at concentrations of 7 ng/ml and 10 ng/ml, respectively, and
co-injected. Following microinjection, cells were cultured for
1, 2 or 6 h at 37 1C to allow protein expression and trafﬁcking.
At the indicated time points cells were ﬁxed with 4% paraformal-
dehyde/PBS and Tetherin-HAint or HA-NTB-A molecules were
detected using a mouse anti-HA mAb (Santa-Cruz) followed by
a goat anti-mouse Alexa568 secondary antibody (Invitrogen).
Newly synthesized Vpu molecules were detected by ﬂuorescence
emission of GFP. Stained cells were imaged with a Zeiss LSM 510
confocal microscope.
Confocal microscopy
HeLa cells were seeded on coverslips and cotransfected with
pNTB-A-2 and either pCG-HIV-1 M NL4-3 wt Vpu-AU1-IRES-GFP,
pCG-HIV-1 M NL4-3 VpuD23-IRES-GFP and pCG-nef STOP-IRES-
GFP. To visualize the Golgi apparatus, cells were additionally
transfected with a pCFP-GalT expression plasmid which encodes
for a galactosyltransferase fusion protein (Rocks et al., 2010).
Immunoﬂuorescence staining was essentially done as described
previously (Koppensteiner et al., 2012). Brieﬂy, 48 h post trans-
fection cells were once washed with PBS and ﬁxed with 2%
paraformaldehyde/PBS for 20 min at 4 1C. Afterwards, cells were
permeabilized with 1% Saponin/PBS for 15 min at RT, followed by
a blocking step using 5% BSA (Bovine serum albumin)/PBS for
45 min at RT. For immunostaining of NTB-A mouse anti-NTBA
(Bio Legend) and goat anti-mouse Alexa555 conjugated secondary
antibody (Invitrogen) was used. The coverslips were mounted on
microscope slides using mowiol mounting solution (2.4 g poly-
vinylalcohol, 6 g Glycerin, 18 ml PBS) and imaged with a Zeiss
LSM510 Meta. For colocalization studies, transfected cells were
selected by GFP expression. Colocalization of NTB-A with the
Golgi-compartment was analyzed by using Imaris (V6.4.2). Per-
centages of Golgi colocalizing with NTB-A were plotted and
statistical analyzes were done using Graph Pad Prism (V5.0).Acknowledgments
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